TCRT

Alaunos Therapeutics, Inc. (TCRT) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder company that has strategically reprioritized away from its clinical-stage TCR-T oncology programs. The Company is currently focused on developing small molecule oral obesity therapeutics (ALN1001) while winding down previous clinical trials. As of March 31, 2025, the Company had 1,601,252 shares of common stock outstanding.

Key Financial Metrics

Debt and Liquidity: The Company has no long-term debt. Current liabilities totaled $1.062 million, primarily accounts payable ($831,000) and accrued expenses ($231,000). Working capital was approximately $5,000 ($1.067M current assets less $1.062M current liabilities).

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately $609,000 (36%) compared to Q1 2024, driven primarily by a significant reduction in General and Administrative (G&A) expenses.
• Expense Management: G&A expenses dropped from $1.617 million to $747,000, a decrease of $870,000 (54%), due to lower employee-related costs, reduced consulting fees, and lower insurance and filing fees.
• R&D Increase: Research and Development expenses increased by $221,000 (175%) to $347,000. This increase is attributed to regulatory writing for wind-down activities and consulting fees related to the new obesity program.
• Cash Burn: Cash reserves declined significantly from $1.091 million at year-end 2024 to $319,000 at March 31, 2025, reflecting a net cash outflow of $772,000 for the quarter.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: Management has identified substantial doubt regarding the Company's ability to continue as a going concern. Cash resources are projected to be sufficient only into the second quarter of 2025. Additional financing is required to fund operations beyond this period.
• Nasdaq Delisting Risk: On April 7, 2025, the Company received a notice from Nasdaq stating that its stockholders' equity ($1.058M at Q1 2025, $2.063M at year-end 2024) fell below the required $2.5 million minimum. The Company has 45 days to submit a compliance plan to avoid delisting.
• Strategic Reprioritization: The Company is actively exploring strategic alternatives, including acquisition, merger, or asset sales. It has engaged Cantor Fitzgerald & Co. as a strategic advisor.
• Subsequent Financing: On April 11, 2025, the Company closed a private offering of Series A-1 Convertible Preferred Stock for an aggregate purchase price of $500,000 to Watermill Asset Management. This stock carries a 10% annual dividend payable in shares and converts to common stock at $2.76 per share.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2025, citing a material weakness in the internal control environment.
• Obesity Program Progress: In vitro testing for the ALN1001 obesity candidate is ongoing, with results expected in Q2 2025. A proof-of-concept mouse study is planned for Q3 2025 pending results and capital availability.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $500,000 raised in April 2025 to extend operations beyond Q2 2025 and the timeline for any additional capital raises.
• Nasdaq Compliance: Monitor the submission and acceptance of the compliance plan regarding the stockholders' equity deficiency to assess delisting risk.
• Strategic Alternatives: Track progress on the strategic review process (mergers, acquisitions, or partnerships) as a potential lifeline for the business.
• Internal Controls: Review the remediation plan for the identified material weakness in internal controls over financial reporting.
• Obesity Program Milestones: Confirm the timeline and results of the in vitro studies for ALN1001, as these are critical for future funding or partnership opportunities.